一项扩展研究,以了解 Fazirsiran 的长期安全性以及 Fazirsiran 是否可以帮助患有 α-1 抗胰蛋白酶肝病的人
一项 3 期开放标签扩展研究,以评估 Fazirsiran 在患有 α-1 抗胰蛋白酶缺乏症相关肝病的参与者中的长期安全性和有效性
The liver produces a protein called alpha-1 antitrypsin (AAT) which is released into the bloodstream. In some people, the liver makes an abnormal version of AAT, called Z-AAT. Z-AAT builds up in liver cells, and over time may lead to liver scarring (fibrosis), severe liver scarring (cirrhosis), and eventually end-stage liver disease. Fazirsiran is a medicine that reduces the production of the abnormal Z-AAT protein and its build-up in the liver.
The main aim of this study is to learn if fazirsiran is safe during long-term use in people with liver disease caused by the abnormal Z-AAT protein. People who have taken part in previous fazirsiran studies (AROAAT2001 [NCT03945292], AROAAT2002 [NCT03946449] , TAK-999-3001 [NCT05677971], or TAK-999-3002 [NCT06165341]) can continue to receive fazirsiran in this study. Participants will receive fazirsian every 3 months, along with health checks, as long as they participate in this study, the study is ongoing or until health authorities in their country approve fazirsiran to be publicly available. The study may also provide information on whether fazirsiran has a long-term effect in reducing liver fibrosis or slowing down the progression of liver fibrosis in people with liver disease due to the abnormal Z-AAT protein.
研究概览
研究类型
注册 (实际的)
阶段
- 第三阶段
联系人和位置
学习地点
-
-
-
Vienna、奥地利、A-1090
- Medizinische Universitat Wien (Medical University of Vienna)
-
-
-
-
North Rhine-Westphalia
-
Aachen、North Rhine-Westphalia、德国、52074
- Universitätsklinikum der RWTH Aachen
-
-
-
-
California
-
La Jolla、California、美国、92037-1337
- UCSD Altman Clinical and Translational Research Institute
-
Redwood City、California、美国、94063
- Stanford Medicine Outpatient Center
-
-
Florida
-
Gainesville、Florida、美国、32610-3010
- UF Clinical and Translational Science Institute
-
-
Iowa
-
Iowa City、Iowa、美国、52242-1009
- University Of Iowa Hospitals And Clinics
-
-
South Carolina
-
Charleston、South Carolina、美国、29425-8900
- Medical University of South Carolina - Hollings Cancer Center - PPDS
-
-
-
-
-
Cambridge、英国、CB2 0QQ
- Addenbrooke's Hospital
-
Edinburgh、英国、EH16 4SA
- Royal Infirmary of Edinburgh - PPDS
-
-
-
-
-
Funchal、葡萄牙、9000-168
- Hospital Nélio Mendonça
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Participants must meet all of the following criteria to be eligible for inclusion in the study:
- The participant is willing and able to understand and fully comply with study procedures and requirements, in the opinion of the investigator.
- The participant is able to read, understand, and complete the study questionnaires electronically per investigator's judgment.
- The participant has provided informed consent (ICF) (that is, in writing, documented via a signed and dated ICF) and any required privacy authorization before the initiation of any study procedures.
Note: For participants who comprehend, can provide informed consent, and are unable to sign the ICF, an impartial witness may sign the ICF on behalf of the participant after the participant has orally consented to the participant's participation in the study.
-
The participant enrolling in this open-label extension (OLE) study will have participated in a previously qualifying study, and will be considered for eligibility based on the following study-specific criteria:
-
AROAAT2001:
- Participants with fibrosis may roll over into this OLE study after they reach their next regularly scheduled, Q12W visit.
- Participants with fibrosis who have completed the AROAAT2001 study may be enrolled into the OLE study.
-
AROAAT2002:
- Participants in Cohorts 1 and 1b may roll over after completing the 24-week primary study period.
- Participants in Cohort 2 may roll over after completing the 48-week primary study period.
- Participants who have completed the study may be enrolled into the OLE study.
-
TAK-999-3001 and TAK-999-3002:
- Participants who have completed the treatment period in Study TAK-999-3001 or TAK-999-3002.
-
The participant is a nonsmoker (defined as: does not smoke cigarettes daily for at least 24 weeks) with current nonsmoking status confirmed by urine cotinine at Day 1.
- E-cigarettes (vapor) are not permitted.
- The participant may be on nicotine replacement (patch or gum). A positive urine cotinine result due to nicotine replacement is acceptable for enrollment at the discretion of the investigator.
-
The participant must have suitable venous access for blood sampling.
-
It must be confirmed that the participant does not have hepatocellular carcinoma (HCC). Participants will be screened for HCC with alpha-fetoprotein (AFP) and abdominal ultrasound. If the participant has any of the following, they will be required to have contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI) imaging to exclude HCC before enrollment.
- AFP >20 nanogram per milliliter (ng/mL).
- AFP 15 to 19 ng/mL at enrollment if that is >2 times prestudy levels (if available).
- Any liver lesion >10 millimeter (mm) (longest diameter) detected by ultrasound.
- Poor visibility of liver on ultrasound.
-
A person of childbearing potential (POCBP) must have a negative urine pregnancy test performed within 3 days prior to Day 1 dosing in this study (sensitive to 25 International Unit [IU] human chorionic gonadotropin [hCG]).
-
The participant must use appropriate contraception methods (that is, highly effective methods for female and medically appropriate methods for male study participants) for the entire duration of the study. Participants who terminate early must use appropriate contraception methods for 6 months after the last dose of study intervention. Male participants who terminate early must not donate sperm for at least 6 months after the last dose of study intervention.
-
Sexual abstinence, for the purposes of this study, is only considered a highly effective method of contraception when considered to align with the preferred and usual lifestyle of the participant. It will be employed for the entire duration of the study and the 6 months after last dose of study intervention.
-
Periodic abstinence (calendar, symptothermal, postovulation methods), withdrawal (coitus interruptus), spermicides only, and lactational amenorrhea methods are not considered "true" abstinence and are not acceptable methods of contraception.
Exclusion Criteria:
- The participant will be excluded from the study if any of the following exclusion criteria are met:
- The participant is likely to require major surgery. Major surgery typically requires at least 1 night in the hospital. Examples include laparoscopic surgery (except cholecystectomy and tubal ligation); Gastrointestinal tract (GI) tract surgery including 1 or more segments of the colon or terminal ileum; open resection of organs; large joint replacements; mastectomy with reconstruction; and spine, thoracic, vascular, or intracranial surgery.
- The participant has evidence of other forms of chronic liver diseases, including viral hepatitis B or C, primary biliary cholangitis, primary sclerosing cholangitis, Wilson disease, alcoholic hepatitis, hemochromatosis, liver cancer, history of biliary diversion, or autoimmune hepatitis.
- The participant has abnormal finding(s) of clinical relevance during the evaluation before the first study dosing that, in the opinion of the investigator, could adversely impact participant safety during the study or adversely impact study results. For US only: Participants with baseline emphysema may be allowed into the OLE if their lung disease has been stable.
- The participant had significant protocol deviation(s) in Study AROAAT2001, AROAAT2002, TAK-999-3001, or TAK-999-3002 that would affect the conduct of this study.
- The participant permanently discontinued investigational product because of an AE, adjudicated as related to the study intervention, in Study AROAAT2001, AROAAT2002, TAK-999-3001, or TAK-999-3002.
- Female participants who became pregnant during Study AROAAT2001, AROAAT2002, TAK-999-3001, or TAK-999-3002, female participants who are lactating or planning to become pregnant during the study period; or males or female participants of childbearing potential not agreeing to continue using appropriate contraception methods through the conclusion of study participation.
- The participant has a Child-Turcotte-Pugh (CTP) score >=7 OR (Model for End-Stage Liver Disease) MELD score >14.
- The participant meets Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) and Creatinine criteria as per the protocol. All laboratory tests used as exclusion criteria may be repeated once and the repeat value may be used for study eligibility determination.
- Participants who have a newly-diagnosed malignancy or recurrence of malignancy (except for resected cutaneous basal cell carcinoma, squamous cell carcinoma, superficial bladder tumors, or carcinoma in situ of the uterine cervix that has been treated with no evidence of recurrence).
- The participant is experiencing a pulmonary exacerbation at the time of enrollment (participant enrollment may be temporarily delayed after the clinical resolution of an exacerbation).
- The participant has unstable, poorly controlled, or severe hypertension. Participants may be reevaluated once their blood pressure is successfully controlled.
- The participant has a history of more than moderate alcohol consumption within 12 months before the Day 1 visit.
- The participant has a history of hypersensitivity or allergies to fazirsiran or any associated excipients.
- The participant has any concomitant medical or psychiatric condition or social situation that would make it difficult to comply with protocol requirements or put the participant at additional safety risk.
- The participant has a history of clinically significant hematologic, renal, hepatic, cardiovascular, infectious, pulmonary, neurologic, psychiatric, GI, systemic inflammatory, metabolic, or endocrine disorder or any other condition that, in the opinion of the investigator, rendered the participant a poor candidate for inclusion into the study.
- The participant has a history of thromboembolic disease (including deep vein thrombosis or pulmonary embolism), within 24 weeks before enrollment; or is taking chronic anticoagulants. (Note: Participants taking stable doses of chronic anticoagulants may be allowed after consultation with the medical monitor, if they do not have cirrhosis or a history of liver decompensating events). Low-dose aspirin may be permitted on-study with the approval of the participant's local healthcare providers and discussion with study medical monitors.
- The participant is unable to return for all scheduled study visits.
- Enrollment of participants with symptomatic coronavirus disease 2019 (COVID-19) infection may be temporarily delayed at the discretion of the sponsor and investigator. Positive antibody testing for COVID-19 without other evidence of symptomatic current or recent active infection does not exclude participation.
- The participant is a study site employee involved in the conduct of this study, an immediate family member (for example, spouse, parent, child, sibling), or is in a dependent relationship with a study site employee who is involved in conduct of this study, or may consent under duress.
- The participant who, in the opinion of the investigator or the sponsor, will be uncooperative or unable to comply with study procedures.
- The participant who participates in other studies involving an investigational product.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Fazirsiran 200 mg
Participants who are currently taking part in or who have completed their treatment in parent studies AROAAT2001 (NCT03945292), AROAAT2002 (NCT03946449), TAK-999-3001 [NCT05677971] and TAK-999-3002 (NCT06165341) will rollover in this study to receive fazirsiran, 200 milligrams (mg), injection, subcutaneously on Day 1 and once every 12 weeks (Q12W) thereafter until fazirsiran receives approval and is commercially available in the participant's country, until a participant withdraws from the study or the sponsor decides to terminate the study. |
Fazirsiran will be injected subcutaneously.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs)
大体时间:From start of study drug administration (in current study) up to End of study (EOS) (current study [up to 10 years])
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of the study intervention, whether or not it is considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study intervention. An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, congenital anomaly/birth defect, suspected transmission of any infectious agent, an important medical event. AEs and SAEs including any pulmonary AEs or SAEs indicative of worsening pulmonary condition (example, pulmonary exacerbation, respiratory infection, significant pulmonary function test decline) will be reported. |
From start of study drug administration (in current study) up to End of study (EOS) (current study [up to 10 years])
|
|
Number of Participants With Clinically Significant Changes From Baseline in Pulmonary Function Parameters
大体时间:Baseline (current study), up to EOS (current study up to 10 years])
|
Standard pulmonary function parameters measured will be used to study lung function. Clinical significance of pulmonary function parameters will be determined at the investigator's discretion. |
Baseline (current study), up to EOS (current study up to 10 years])
|
|
Number of Participants With Clinically Significant Changes in Vital Signs
大体时间:From start of study drug administration (in current study) up to EOS (current study [up to 10 years])
|
Vital signs include body temperature, respiratory rate, sitting blood pressure (systolic and diastolic, resting more than 5 minutes), pulse, oxygen saturation. Clinical significance of vital signs will be determined at the investigator's discretion. |
From start of study drug administration (in current study) up to EOS (current study [up to 10 years])
|
|
Number of Participants With Clinically Significant Changes in Laboratory Parameters
大体时间:From start of study drug administration (in current study) up to EOS (current study [up to 10 years])
|
Laboratory parameters include hematology, biochemistry including liver tests, coagulation, and urinalysis. Clinical significance of laboratory parameters will be determined at the investigator's discretion. |
From start of study drug administration (in current study) up to EOS (current study [up to 10 years])
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of Participants With no Progression from Baseline of At least 1 Stage of Histologic Fibrosis on Liver Biopsy at Week 102
大体时间:At Week 102 (current study)
|
Number of participants from Studies AROAAT2001 and AROAAT2002 with no progression from baseline of at least 1 stage of histologic fibrosis (by Meta-Analysis of Histological Data in Viral Hepatitis [METAVIR] staging) on liver biopsy at Week 102 will be reported. |
At Week 102 (current study)
|
|
Number of Participants With Reduction from Baseline of At least 1 Stage of Histologic Fibrosis on Liver Biopsy at Week 102
大体时间:At Week 102 (current study)
|
Number of participants from Studies AROAAT2001 and AROAAT2002 with baseline fibrosis of F1 or higher, a decrease from baseline of at least 1 stage of histologic fibrosis (by METAVIR staging) on liver biopsy at Week 102 will be reported. |
At Week 102 (current study)
|
|
Change from Baseline in Intrahepatic Z-AAT Protein Polymer Burden Assessed by Periodic Acid Schiff Plus Diastase (PAS+D) Staining in Liver Biopsy at Week 102
大体时间:Baseline (current study), Week 102 (current study)
|
Change from baseline in intrahepatic Z-AAT protein polymer burden assessed by PAS+D staining in liver biopsy for participants from Studies AROAAT2001 and AROAAT2002 will be assessed. |
Baseline (current study), Week 102 (current study)
|
|
Change from Baseline in Intrahepatic Portal Inflammation Score at Week 102 in Liver Biopsy
大体时间:Baseline (current study), Week 102 (current study)
|
Change in portal inflammation score in liver biopsy, based on pathology slide reads for participants from Studies AROAAT2001 and AROAAT2002 will be assessed. Inflammation will be assessed on a scale of 0-3, with higher scores showing more severe inflammation. |
Baseline (current study), Week 102 (current study)
|
|
Change from Baseline in Liver Stiffness Assessed by Magnetic Resonance Elastography (MRE)
大体时间:Baseline (current study), up to EOS (current study up to 10 years])
|
Change from baseline in MRE-derived liver stiffness will be assessed. |
Baseline (current study), up to EOS (current study up to 10 years])
|
|
Change from Baseline in Liver Stiffness Assessed by Vibration-Controlled Transient Elastography (VCTE)
大体时间:Baseline (current study), up to EOS (current study up to 10 years])
|
Change from baseline in VCTE-derived liver stiffness will be assessed. |
Baseline (current study), up to EOS (current study up to 10 years])
|
合作者和调查者
赞助
调查人员
- 研究主任:Study Director、Takeda
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- TAK-999-3003
- 2023-503497-21-00 (克蒂斯:EU CTIS)
- 2023 (美国 NIH 拨款/合同)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
IPD 共享访问标准
IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
IPD 共享支持信息类型
- 研究方案
- 树液
- 国际碳纤维联合会
- 企业社会责任
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.